Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study

BACKGROUND: Immune checkpoint inhibitor (ICI), coupled with systemic chemotherapy, may enhance the clinical benefit of cancer by potentiating antitumor immunity, but its efficacy and safety are not clear in advanced intrahepatic cholangiocarcinoma (ICC). This study aims to assess the efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu-Qing, Wang, Kang, Feng, Jin-Kai, Yuan, Lu-Yun, Liang, Chao, Xiang, Yan-Jun, Wang, Xu, Mao, Fei-Fei, Cheng, Shu-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183568/
https://www.ncbi.nlm.nih.gov/pubmed/37197414
http://dx.doi.org/10.3389/fonc.2023.1101038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183568/
https://www.ncbi.nlm.nih.gov/pubmed/37197414
http://dx.doi.org/10.3389/fonc.2023.1101038

Ejemplares similares